Provided by Tiger Trade Technology Pte. Ltd.

Jade Biosciences

17.89
-1.2500-6.53%
Post-market: 17.890.00000.00%19:30 EDT
Volume:1.25M
Turnover:23.06M
Market Cap:1.14B
PE:-7.63
High:20.10
Open:19.38
Low:17.53
Close:19.14
52wk High:28.00
52wk Low:6.91
Shares:63.60M
Float Shares:47.12M
Volume Ratio:1.13
T/O Rate:2.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3433
EPS(LYR):-3.1931
ROE:-89.18%
ROA:-33.59%
PB:0.39
PE(LYR):-5.60

Loading ...

BRIEF-Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101

Reuters
·
Jun 01

Jade Biosciences - Phase 3 Registrational Trial Expected to Initiate in First Half of 2027

THOMSON REUTERS
·
Jun 01

Jade Biosciences - Jade101 Well-Tolerated Across All Evaluated Doses

THOMSON REUTERS
·
Jun 01

Jade Biosciences - Jade101 Sustains ~70% Iga Reduction at 12 Weeks After Single Dose

THOMSON REUTERS
·
Jun 01

Jade Biosciences reports positive interim Phase 1 data for JADE101 in IgA nephropathy, targets Q12W dosing

Reuters
·
Jun 01

Jade Biosciences to present interim Phase 1 healthy volunteer data for JADE101 in IgA nephropathy on June 1 webcast

Reuters
·
May 30

Jade Biosciences’ JADE101 Trial Opens a New Front in IgA Nephropathy Investing

TIPRANKS
·
May 30

Guggenheim Sticks to Their Buy Rating for Jade Biosciences (JBIO)

TIPRANKS
·
May 27

Jade Biosciences Price Target Maintained With a $39.00/Share by BTIG

Dow Jones
·
May 27

BRIEF-Jade Biosciences Announces First Participant Dosed In First-In-Human Phase 1 Clinical Trial Of Jade201

Reuters
·
May 27

Jade Biosciences doses first participant in Phase 1 trial of autoimmune drug candidate JADE201

Reuters
·
May 27

Jade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of Jade201, a Novel Half-Life Extended Afucosylated Anti-Baff Receptor Monoclonal Antibody

THOMSON REUTERS
·
May 27

Jade Biosciences Doses First Patient in Phase 2 Study of Kidney Disease Therapy

MT Newswires Live
·
May 26

Jade Biosciences Announces First Participant Dosed in Phase 2 Juniper Clinical Trial of Jade101 in Iga Nephropathy

THOMSON REUTERS
·
May 26

Jade Biosciences Inc - Interim Data From Juniper Phase 2 Trial Expected in 2027

THOMSON REUTERS
·
May 26

BRIEF-Jade Biosciences Inc - Prospectus Filed For Resale Of Up To 39,542,339 Shares By Selling Stockholders - SEC Filing

Reuters
·
May 16

Jade Biosciences price target raised to $34 from $24 at Wedbush

TIPRANKS
·
May 12

Jade Biosciences Is Maintained at Outperform by Wedbush

Dow Jones
·
May 11

Jade Biosciences Inc : Guggenheim Raises Target Price to $32 From $23

THOMSON REUTERS
·
May 11

Stock Track | Jade Biosciences Soars 5.45% Intraday on Analyst Price Target Hikes and Upcoming Pipeline Catalysts

Stock Track
·
May 08